Last reviewed · How we verify
AS MDI
AS MDI is a metered-dose inhaler formulation that delivers an active pharmaceutical agent directly to the respiratory tract for local and/or systemic therapeutic effect.
At a glance
| Generic name | AS MDI |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
AS MDI represents a delivery system rather than a novel molecular entity. The specific mechanism depends on the active ingredient contained within the formulation. As an MDI (metered-dose inhaler), it is designed to provide precise, reproducible doses of medication via inhalation, targeting pulmonary and/or systemic pathways depending on the drug's properties and intended indication.
Approved indications
Common side effects
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Ventilation and Perfusion in Asthmatics (PHASE4)
- Treatment Response In ECT Patients
- A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (PHASE1)
- The Effect of İnhaler Training and Reminders on Medication on Adherence in Elderly Individuals (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AS MDI CI brief — competitive landscape report
- AS MDI updates RSS · CI watch RSS
- AstraZeneca portfolio CI